NEURAD · Neurodegeneration in Alzheimer's disease - mechanisms, consequences and therapy
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2006-04-01 → 2010-03-31
- EU contribution
- €1,784,190
- Participants
- 12
- Scheme
- EST
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - NEURAD (Neurodegeneration in Alzheimer's disease - mechanisms, consequences and therapy)
Alzheimer's disease (AD) research is one of the most competitive fields in neuroscience. Surprisingly, despite the fact that important molecular players involved in the pathology of AD are well known and investigated, therapeutic improvements are lacking. The numbers of AD patients are expected to increase dramatically within the near future with drastic socio-economical consequences. In the past few years, however, several promising novel approaches have been described. The neuropathology of AD is characterised by aggregates of extracellular beta-amyloid, the formation of neurofibrillary tangles, neuronal and synaptic dysfunction and loss of neurons and synapses. One of the most challenging aspects of the elucidation of AD pathogenesis is unravelling putative associations and causative links between these AD hallmarks. In 2006, the European Commission funded a consortium of AD scientists from European universities and pharmaceutical companies, who subsequently implemented a Marie Curie Early Stage Training site named 'Neurodegeneration in Alzheimer's disease - mechanisms, consequences and therapy' (NEURAD - acronym for 'neuron' and 'AD' see http://www.neurad-alzheimer.de online). The common theme of the consortium was to study the early pathological mechanisms of AD and the consequences for the physiology of neuronal networks and for deficits in memory, with the implementation and verification of novel therapeutic approaches for AD being one of its main targets. As part of the training program for the NEURAD early stage researchers several symposia, workshops and summer schools were organised. All NEURAD activities were well attended and an active network of academic groups and private companies has been formed with joint PhD student training activities. Within NEURAD several important findings were published some of them patented. For example one new target for AD has been identified, which has fuelled several projects and collaborations.
Data: CORDIS, © European Union
Project objective
The aim of this project is to provide structured research training for early stage researchers in the field of Neurosciences, with special emphasis on Alzheimer's disease (AD). Due to the demographical development of societies in industrialized countries, the number of AD patients will increase dramatically within the next years.Thus, the demand for well-trained scientists in pharmaceutical companies and academic research units focussing on AD is expected to rise. To be able to meet the future requirements, a consortium of AD scientists from 9 universities have gathered to implement a Marie Curie Early Stage Training, named NEURAD (acronym for neuron" and "AD") together with one pharmaceutical company and two SMEs.The common theme of the consortium is to study the early patho-mechanisms of AD, the consequences for the physiology of neuronal networks and for deficits in memory, with the implementation and verification of novel therapeutic approaches for AD being one of its main targets.The fellows will be trained in four complementary modules.Mandatory:- Interdisciplinary experimental training in another university based laboratories within the consortium for at least 6 months.- Multidisciplinary courses in AD research and management skills during an annual two-week summer school as complementary training.- An intersectional 3 months research training in a laboratory of the pharmaceutical partners.Optional:- One-month clinical internship in a clinical memory unit. These actions will manifest the mobility of the fellows in a European perspective, and implement the truly interdisciplinary, interscectional and multidisciplinary character of the NEURAD initiative."
Original text from CORDIS.
Participants
- UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OFFENTLICHEN RECHTSCoordinatorCity levelGermany
- FREIE UNIVERSITAET BERLIN · BERLINGermany
- HEINRICH-HEINE UNIVERSITAT DUESSELDORFCity levelGermany
- INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE · PARISCity levelFrance
- JOHANNES GUTENBERG UNIVERSITAET MAINZ · MAINZGermany
- KATHOLIEKE UNIVERSITEIT LEUVEN · LEUVENBelgium
- UNIVERSITE DE POITIERS · POITIERSFrance
- UNIVERSITE PARIS 7 DIDEROT · PARISCity levelFrance
- UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 · PARISFrance
- UNIVERSITEIT MAASTRICHT · MAASTRICHTNetherlands
- UNIVERSITEIT VAN AMSTERDAM · AMSTERDAMNetherlands
- Universität des Saarlandes · SaarbrückenGermany
Links
Data: CORDIS, © European Union